Rebamipide: New opportunities of gastroenteroprotection
This review paper deals with the prevention and therapy of nonsteroidal anti-inflammatory drug (NSAID)-induced gastrointestinal mucosal injuries in patients with diseases of the cardiovascular and locomotor systems. Particular emphasis is laid on the new Russian drug rebamibide that is a stimulant o...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
V I Simanenkov [verfasserIn] S V Tikhonov [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Russisch |
| Erschienen: |
2015 |
|---|
| Schlagwörter: |
|---|
| Übergeordnetes Werk: |
In: Терапевтический архив - "Consilium Medicum" Publishing house, 2018, 87(2015), 12, Seite 134-137 |
|---|---|
| Übergeordnetes Werk: |
volume:87 ; year:2015 ; number:12 ; pages:134-137 |
| Links: |
|---|
| Katalog-ID: |
DOAJ003526925 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ003526925 | ||
| 003 | DE-627 | ||
| 005 | 20230309174904.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230225s2015 xx |||||o 00| ||rus c | ||
| 035 | |a (DE-627)DOAJ003526925 | ||
| 035 | |a (DE-599)DOAJcc64e31f17e34da5aa2b275550a0dd3b | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a rus | ||
| 100 | 0 | |a V I Simanenkov |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Rebamipide: New opportunities of gastroenteroprotection |
| 264 | 1 | |c 2015 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a This review paper deals with the prevention and therapy of nonsteroidal anti-inflammatory drug (NSAID)-induced gastrointestinal mucosal injuries in patients with diseases of the cardiovascular and locomotor systems. Particular emphasis is laid on the new Russian drug rebamibide that is a stimulant of prostaglandin and glycoprotein synthesis and an inhibitor of the synthesis of oxidative stress products, inflammatory cytokines, and chemokines in the gastrointestinal mucosa. The advantage of rebamipide over classical gastroprotectors is its proven additional effect on the small and large intestinal mucosa. This drug has been registered and is actively used in a number of countries, including Japan, South Korea, and China. | ||
| 650 | 4 | |a rebamipide | |
| 650 | 4 | |a nonsteroidal anti-inflammatory drugs (nsaid) | |
| 650 | 4 | |a nsaid gastropathy | |
| 650 | 4 | |a nsaid enteropathy | |
| 653 | 0 | |a Medicine | |
| 653 | 0 | |a R | |
| 700 | 0 | |a S V Tikhonov |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t Терапевтический архив |d "Consilium Medicum" Publishing house, 2018 |g 87(2015), 12, Seite 134-137 |w (DE-627)1760620270 |x 23095342 |7 nnns |
| 773 | 1 | 8 | |g volume:87 |g year:2015 |g number:12 |g pages:134-137 |
| 856 | 4 | 0 | |u https://doaj.org/article/cc64e31f17e34da5aa2b275550a0dd3b |z kostenfrei |
| 856 | 4 | 0 | |u https://ter-arkhiv.ru/0040-3660/article/view/31896 |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/0040-3660 |y Journal toc |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/2309-5342 |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 951 | |a AR | ||
| 952 | |d 87 |j 2015 |e 12 |h 134-137 | ||
| author_variant |
v i s vis s v t svt |
|---|---|
| matchkey_str |
article:23095342:2015----::eaiieeopruiisfaton |
| hierarchy_sort_str |
2015 |
| publishDate |
2015 |
| allfields |
(DE-627)DOAJ003526925 (DE-599)DOAJcc64e31f17e34da5aa2b275550a0dd3b DE-627 ger DE-627 rakwb rus V I Simanenkov verfasserin aut Rebamipide: New opportunities of gastroenteroprotection 2015 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier This review paper deals with the prevention and therapy of nonsteroidal anti-inflammatory drug (NSAID)-induced gastrointestinal mucosal injuries in patients with diseases of the cardiovascular and locomotor systems. Particular emphasis is laid on the new Russian drug rebamibide that is a stimulant of prostaglandin and glycoprotein synthesis and an inhibitor of the synthesis of oxidative stress products, inflammatory cytokines, and chemokines in the gastrointestinal mucosa. The advantage of rebamipide over classical gastroprotectors is its proven additional effect on the small and large intestinal mucosa. This drug has been registered and is actively used in a number of countries, including Japan, South Korea, and China. rebamipide nonsteroidal anti-inflammatory drugs (nsaid) nsaid gastropathy nsaid enteropathy Medicine R S V Tikhonov verfasserin aut In Терапевтический архив "Consilium Medicum" Publishing house, 2018 87(2015), 12, Seite 134-137 (DE-627)1760620270 23095342 nnns volume:87 year:2015 number:12 pages:134-137 https://doaj.org/article/cc64e31f17e34da5aa2b275550a0dd3b kostenfrei https://ter-arkhiv.ru/0040-3660/article/view/31896 kostenfrei https://doaj.org/toc/0040-3660 Journal toc kostenfrei https://doaj.org/toc/2309-5342 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ AR 87 2015 12 134-137 |
| spelling |
(DE-627)DOAJ003526925 (DE-599)DOAJcc64e31f17e34da5aa2b275550a0dd3b DE-627 ger DE-627 rakwb rus V I Simanenkov verfasserin aut Rebamipide: New opportunities of gastroenteroprotection 2015 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier This review paper deals with the prevention and therapy of nonsteroidal anti-inflammatory drug (NSAID)-induced gastrointestinal mucosal injuries in patients with diseases of the cardiovascular and locomotor systems. Particular emphasis is laid on the new Russian drug rebamibide that is a stimulant of prostaglandin and glycoprotein synthesis and an inhibitor of the synthesis of oxidative stress products, inflammatory cytokines, and chemokines in the gastrointestinal mucosa. The advantage of rebamipide over classical gastroprotectors is its proven additional effect on the small and large intestinal mucosa. This drug has been registered and is actively used in a number of countries, including Japan, South Korea, and China. rebamipide nonsteroidal anti-inflammatory drugs (nsaid) nsaid gastropathy nsaid enteropathy Medicine R S V Tikhonov verfasserin aut In Терапевтический архив "Consilium Medicum" Publishing house, 2018 87(2015), 12, Seite 134-137 (DE-627)1760620270 23095342 nnns volume:87 year:2015 number:12 pages:134-137 https://doaj.org/article/cc64e31f17e34da5aa2b275550a0dd3b kostenfrei https://ter-arkhiv.ru/0040-3660/article/view/31896 kostenfrei https://doaj.org/toc/0040-3660 Journal toc kostenfrei https://doaj.org/toc/2309-5342 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ AR 87 2015 12 134-137 |
| allfields_unstemmed |
(DE-627)DOAJ003526925 (DE-599)DOAJcc64e31f17e34da5aa2b275550a0dd3b DE-627 ger DE-627 rakwb rus V I Simanenkov verfasserin aut Rebamipide: New opportunities of gastroenteroprotection 2015 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier This review paper deals with the prevention and therapy of nonsteroidal anti-inflammatory drug (NSAID)-induced gastrointestinal mucosal injuries in patients with diseases of the cardiovascular and locomotor systems. Particular emphasis is laid on the new Russian drug rebamibide that is a stimulant of prostaglandin and glycoprotein synthesis and an inhibitor of the synthesis of oxidative stress products, inflammatory cytokines, and chemokines in the gastrointestinal mucosa. The advantage of rebamipide over classical gastroprotectors is its proven additional effect on the small and large intestinal mucosa. This drug has been registered and is actively used in a number of countries, including Japan, South Korea, and China. rebamipide nonsteroidal anti-inflammatory drugs (nsaid) nsaid gastropathy nsaid enteropathy Medicine R S V Tikhonov verfasserin aut In Терапевтический архив "Consilium Medicum" Publishing house, 2018 87(2015), 12, Seite 134-137 (DE-627)1760620270 23095342 nnns volume:87 year:2015 number:12 pages:134-137 https://doaj.org/article/cc64e31f17e34da5aa2b275550a0dd3b kostenfrei https://ter-arkhiv.ru/0040-3660/article/view/31896 kostenfrei https://doaj.org/toc/0040-3660 Journal toc kostenfrei https://doaj.org/toc/2309-5342 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ AR 87 2015 12 134-137 |
| allfieldsGer |
(DE-627)DOAJ003526925 (DE-599)DOAJcc64e31f17e34da5aa2b275550a0dd3b DE-627 ger DE-627 rakwb rus V I Simanenkov verfasserin aut Rebamipide: New opportunities of gastroenteroprotection 2015 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier This review paper deals with the prevention and therapy of nonsteroidal anti-inflammatory drug (NSAID)-induced gastrointestinal mucosal injuries in patients with diseases of the cardiovascular and locomotor systems. Particular emphasis is laid on the new Russian drug rebamibide that is a stimulant of prostaglandin and glycoprotein synthesis and an inhibitor of the synthesis of oxidative stress products, inflammatory cytokines, and chemokines in the gastrointestinal mucosa. The advantage of rebamipide over classical gastroprotectors is its proven additional effect on the small and large intestinal mucosa. This drug has been registered and is actively used in a number of countries, including Japan, South Korea, and China. rebamipide nonsteroidal anti-inflammatory drugs (nsaid) nsaid gastropathy nsaid enteropathy Medicine R S V Tikhonov verfasserin aut In Терапевтический архив "Consilium Medicum" Publishing house, 2018 87(2015), 12, Seite 134-137 (DE-627)1760620270 23095342 nnns volume:87 year:2015 number:12 pages:134-137 https://doaj.org/article/cc64e31f17e34da5aa2b275550a0dd3b kostenfrei https://ter-arkhiv.ru/0040-3660/article/view/31896 kostenfrei https://doaj.org/toc/0040-3660 Journal toc kostenfrei https://doaj.org/toc/2309-5342 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ AR 87 2015 12 134-137 |
| allfieldsSound |
(DE-627)DOAJ003526925 (DE-599)DOAJcc64e31f17e34da5aa2b275550a0dd3b DE-627 ger DE-627 rakwb rus V I Simanenkov verfasserin aut Rebamipide: New opportunities of gastroenteroprotection 2015 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier This review paper deals with the prevention and therapy of nonsteroidal anti-inflammatory drug (NSAID)-induced gastrointestinal mucosal injuries in patients with diseases of the cardiovascular and locomotor systems. Particular emphasis is laid on the new Russian drug rebamibide that is a stimulant of prostaglandin and glycoprotein synthesis and an inhibitor of the synthesis of oxidative stress products, inflammatory cytokines, and chemokines in the gastrointestinal mucosa. The advantage of rebamipide over classical gastroprotectors is its proven additional effect on the small and large intestinal mucosa. This drug has been registered and is actively used in a number of countries, including Japan, South Korea, and China. rebamipide nonsteroidal anti-inflammatory drugs (nsaid) nsaid gastropathy nsaid enteropathy Medicine R S V Tikhonov verfasserin aut In Терапевтический архив "Consilium Medicum" Publishing house, 2018 87(2015), 12, Seite 134-137 (DE-627)1760620270 23095342 nnns volume:87 year:2015 number:12 pages:134-137 https://doaj.org/article/cc64e31f17e34da5aa2b275550a0dd3b kostenfrei https://ter-arkhiv.ru/0040-3660/article/view/31896 kostenfrei https://doaj.org/toc/0040-3660 Journal toc kostenfrei https://doaj.org/toc/2309-5342 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ AR 87 2015 12 134-137 |
| language |
Russian |
| source |
In Терапевтический архив 87(2015), 12, Seite 134-137 volume:87 year:2015 number:12 pages:134-137 |
| sourceStr |
In Терапевтический архив 87(2015), 12, Seite 134-137 volume:87 year:2015 number:12 pages:134-137 |
| format_phy_str_mv |
Article |
| institution |
findex.gbv.de |
| topic_facet |
rebamipide nonsteroidal anti-inflammatory drugs (nsaid) nsaid gastropathy nsaid enteropathy Medicine R |
| isfreeaccess_bool |
true |
| container_title |
Терапевтический архив |
| authorswithroles_txt_mv |
V I Simanenkov @@aut@@ S V Tikhonov @@aut@@ |
| publishDateDaySort_date |
2015-01-01T00:00:00Z |
| hierarchy_top_id |
1760620270 |
| id |
DOAJ003526925 |
| language_de |
russisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ003526925</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230309174904.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230225s2015 xx |||||o 00| ||rus c</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ003526925</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJcc64e31f17e34da5aa2b275550a0dd3b</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">rus</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">V I Simanenkov</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Rebamipide: New opportunities of gastroenteroprotection</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2015</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">This review paper deals with the prevention and therapy of nonsteroidal anti-inflammatory drug (NSAID)-induced gastrointestinal mucosal injuries in patients with diseases of the cardiovascular and locomotor systems. Particular emphasis is laid on the new Russian drug rebamibide that is a stimulant of prostaglandin and glycoprotein synthesis and an inhibitor of the synthesis of oxidative stress products, inflammatory cytokines, and chemokines in the gastrointestinal mucosa. The advantage of rebamipide over classical gastroprotectors is its proven additional effect on the small and large intestinal mucosa. This drug has been registered and is actively used in a number of countries, including Japan, South Korea, and China.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">rebamipide</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">nonsteroidal anti-inflammatory drugs (nsaid)</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">nsaid gastropathy</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">nsaid enteropathy</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Medicine</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">R</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">S V Tikhonov</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Терапевтический архив</subfield><subfield code="d">"Consilium Medicum" Publishing house, 2018</subfield><subfield code="g">87(2015), 12, Seite 134-137</subfield><subfield code="w">(DE-627)1760620270</subfield><subfield code="x">23095342</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:87</subfield><subfield code="g">year:2015</subfield><subfield code="g">number:12</subfield><subfield code="g">pages:134-137</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/cc64e31f17e34da5aa2b275550a0dd3b</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://ter-arkhiv.ru/0040-3660/article/view/31896</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/0040-3660</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2309-5342</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">87</subfield><subfield code="j">2015</subfield><subfield code="e">12</subfield><subfield code="h">134-137</subfield></datafield></record></collection>
|
| author |
V I Simanenkov |
| spellingShingle |
V I Simanenkov misc rebamipide misc nonsteroidal anti-inflammatory drugs (nsaid) misc nsaid gastropathy misc nsaid enteropathy misc Medicine misc R Rebamipide: New opportunities of gastroenteroprotection |
| authorStr |
V I Simanenkov |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)1760620270 |
| format |
electronic Article |
| delete_txt_mv |
keep |
| author_role |
aut aut |
| collection |
DOAJ |
| remote_str |
true |
| illustrated |
Not Illustrated |
| issn |
23095342 |
| topic_title |
Rebamipide: New opportunities of gastroenteroprotection rebamipide nonsteroidal anti-inflammatory drugs (nsaid) nsaid gastropathy nsaid enteropathy |
| topic |
misc rebamipide misc nonsteroidal anti-inflammatory drugs (nsaid) misc nsaid gastropathy misc nsaid enteropathy misc Medicine misc R |
| topic_unstemmed |
misc rebamipide misc nonsteroidal anti-inflammatory drugs (nsaid) misc nsaid gastropathy misc nsaid enteropathy misc Medicine misc R |
| topic_browse |
misc rebamipide misc nonsteroidal anti-inflammatory drugs (nsaid) misc nsaid gastropathy misc nsaid enteropathy misc Medicine misc R |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
cr |
| hierarchy_parent_title |
Терапевтический архив |
| hierarchy_parent_id |
1760620270 |
| hierarchy_top_title |
Терапевтический архив |
| isfreeaccess_txt |
true |
| familylinks_str_mv |
(DE-627)1760620270 |
| title |
Rebamipide: New opportunities of gastroenteroprotection |
| ctrlnum |
(DE-627)DOAJ003526925 (DE-599)DOAJcc64e31f17e34da5aa2b275550a0dd3b |
| title_full |
Rebamipide: New opportunities of gastroenteroprotection |
| author_sort |
V I Simanenkov |
| journal |
Терапевтический архив |
| journalStr |
Терапевтический архив |
| lang_code |
rus |
| isOA_bool |
true |
| recordtype |
marc |
| publishDateSort |
2015 |
| contenttype_str_mv |
txt |
| container_start_page |
134 |
| author_browse |
V I Simanenkov S V Tikhonov |
| container_volume |
87 |
| format_se |
Elektronische Aufsätze |
| author-letter |
V I Simanenkov |
| author2-role |
verfasserin |
| title_sort |
rebamipide: new opportunities of gastroenteroprotection |
| title_auth |
Rebamipide: New opportunities of gastroenteroprotection |
| abstract |
This review paper deals with the prevention and therapy of nonsteroidal anti-inflammatory drug (NSAID)-induced gastrointestinal mucosal injuries in patients with diseases of the cardiovascular and locomotor systems. Particular emphasis is laid on the new Russian drug rebamibide that is a stimulant of prostaglandin and glycoprotein synthesis and an inhibitor of the synthesis of oxidative stress products, inflammatory cytokines, and chemokines in the gastrointestinal mucosa. The advantage of rebamipide over classical gastroprotectors is its proven additional effect on the small and large intestinal mucosa. This drug has been registered and is actively used in a number of countries, including Japan, South Korea, and China. |
| abstractGer |
This review paper deals with the prevention and therapy of nonsteroidal anti-inflammatory drug (NSAID)-induced gastrointestinal mucosal injuries in patients with diseases of the cardiovascular and locomotor systems. Particular emphasis is laid on the new Russian drug rebamibide that is a stimulant of prostaglandin and glycoprotein synthesis and an inhibitor of the synthesis of oxidative stress products, inflammatory cytokines, and chemokines in the gastrointestinal mucosa. The advantage of rebamipide over classical gastroprotectors is its proven additional effect on the small and large intestinal mucosa. This drug has been registered and is actively used in a number of countries, including Japan, South Korea, and China. |
| abstract_unstemmed |
This review paper deals with the prevention and therapy of nonsteroidal anti-inflammatory drug (NSAID)-induced gastrointestinal mucosal injuries in patients with diseases of the cardiovascular and locomotor systems. Particular emphasis is laid on the new Russian drug rebamibide that is a stimulant of prostaglandin and glycoprotein synthesis and an inhibitor of the synthesis of oxidative stress products, inflammatory cytokines, and chemokines in the gastrointestinal mucosa. The advantage of rebamipide over classical gastroprotectors is its proven additional effect on the small and large intestinal mucosa. This drug has been registered and is actively used in a number of countries, including Japan, South Korea, and China. |
| collection_details |
GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ |
| container_issue |
12 |
| title_short |
Rebamipide: New opportunities of gastroenteroprotection |
| url |
https://doaj.org/article/cc64e31f17e34da5aa2b275550a0dd3b https://ter-arkhiv.ru/0040-3660/article/view/31896 https://doaj.org/toc/0040-3660 https://doaj.org/toc/2309-5342 |
| remote_bool |
true |
| author2 |
S V Tikhonov |
| author2Str |
S V Tikhonov |
| ppnlink |
1760620270 |
| mediatype_str_mv |
c |
| isOA_txt |
true |
| hochschulschrift_bool |
false |
| up_date |
2024-07-03T18:31:39.820Z |
| _version_ |
1803583749955256320 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ003526925</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230309174904.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230225s2015 xx |||||o 00| ||rus c</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ003526925</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJcc64e31f17e34da5aa2b275550a0dd3b</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">rus</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">V I Simanenkov</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Rebamipide: New opportunities of gastroenteroprotection</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2015</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">This review paper deals with the prevention and therapy of nonsteroidal anti-inflammatory drug (NSAID)-induced gastrointestinal mucosal injuries in patients with diseases of the cardiovascular and locomotor systems. Particular emphasis is laid on the new Russian drug rebamibide that is a stimulant of prostaglandin and glycoprotein synthesis and an inhibitor of the synthesis of oxidative stress products, inflammatory cytokines, and chemokines in the gastrointestinal mucosa. The advantage of rebamipide over classical gastroprotectors is its proven additional effect on the small and large intestinal mucosa. This drug has been registered and is actively used in a number of countries, including Japan, South Korea, and China.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">rebamipide</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">nonsteroidal anti-inflammatory drugs (nsaid)</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">nsaid gastropathy</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">nsaid enteropathy</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Medicine</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">R</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">S V Tikhonov</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Терапевтический архив</subfield><subfield code="d">"Consilium Medicum" Publishing house, 2018</subfield><subfield code="g">87(2015), 12, Seite 134-137</subfield><subfield code="w">(DE-627)1760620270</subfield><subfield code="x">23095342</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:87</subfield><subfield code="g">year:2015</subfield><subfield code="g">number:12</subfield><subfield code="g">pages:134-137</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/cc64e31f17e34da5aa2b275550a0dd3b</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://ter-arkhiv.ru/0040-3660/article/view/31896</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/0040-3660</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2309-5342</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">87</subfield><subfield code="j">2015</subfield><subfield code="e">12</subfield><subfield code="h">134-137</subfield></datafield></record></collection>
|
| score |
7.400523 |